Sibutramine sensitivity assay revealed a unique phenotype of bombesin BB3 receptor-deficient mice

European Journal of Pharmacology

Volumn 473, Issue 1, 2003, Pages 41-46

  Matsumoto, Kouji ^a   Iijima, Hiroaki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Animal model; Bombesin BB3 receptor (BRS 3); Energy efficiency; Hyperphagia; Serotonin and noradrenaline re uptake inhibitor (SNRI); Sibutramine

Indexed keywords

BOMBESIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG DETERMINATION; DRUG SENSITIVITY; ENERGY CONSUMPTION; FEMALE; FOOD INTAKE; HYPERPHAGIA; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; SPECIES COMPARISON; SPECIES DIFFERENCE; WILD TYPE;

EID: 0037769960     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01908-3     Document Type: Article

References (37)

1. Battey J.F., Way J.M., Corjay M.H., Shapira H., Kusano K., Harkins R., Wu J.M., Slattery T., Mann E., Feldman R.I. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc. Natl. Acad. Sci. U. S. A. 88:1991;395-399.
2. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jain A.K., Mendel C.M., Mendels J., Ryan D.H., Schwartz S.L., Scheinbaum M.L., Seaton T.B. Sibutramine produces dose-related weight loss. Obes. Res. 7(2):1999;189-198.
3. Bultman S.J., Michaud E.J., Woychik R.P. Molecular characterization of the mouse agouti locus. Cell. 71:1992;1195-1204.
4. Carek P.J., Dickerson L.M. Current concepts in the pharmacological management of obesity. Drugs. 57(6):1999;883-904.
5. Coleman D.L. Therapeutic effects of dehydroepiandrosterone (DHEA) and its metabolites in obese-hyperglycemic mutant mice. Prog. Clin. Biol. Res. 265:1988;161-175.
6. Corjay M.H., Dobrzanski D.J., Way J.M., Viallet J., Shapira H., Worland P., Sausville E.A., Battey J.F. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J. Biol. Chem. 266:1991;18771-18779.
7. De Fanti B.A., Gavel D.A., Hamilton J.S., Horwitz B.A. Extracellular hypothalamic serotonin levels after dorsal raphe nuclei stimulation of lean (Fa/Fa) and obese (fa/fa) Zucker rats. Brain Res. 869:2000;6-14.
8. De Fanti B.A., Hamilton J.S., Horwitz B.A. Meal-induced changes in extracellular 5-HT in medial hypothalamus of lean (Fa/Fa) and obese (fa/fa) Zucker rats. Brain Res. 902:2001;164-170.
9. Fathi Z., Corjay M.H., Shapira H., Wada E., Benya R., Jensen R., Viallet J., Sausville E.A., Battey J.F. BRS-3: a novel bombesin receptor subtype selectively expressed testis and lung carcinoma cells. J. Biol. Chem. 268:1993;5979-5984.
10. Garris D.R. Age- and diabetes-associated alterations in regional brain norepinephrine concentrations and adrenergic receptor populations in C57BL/KsJ mice. Brain Res., Dev. Brain Res. 51(2):1990;161-166.
11. Gorbulev V., Akhundova A., Buchner H., Fahrenholz F. Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy. Eur. J. Biochem. 208:1992;405-410.
12. Heal D.J., Aspley S., Prow M.R., Jackson H.C., Martin K.F., Cheetham S.C. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int. J. Obes. 22(Supplement 1):1998;S18-S28.
13. Herberg L., Coleman D.L. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism. 26:1997;59-87.
14. Iwatsuka H., Shino A., Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol. Jpn. 17:1970;25-35.
15. Jackson H.C., Bearham M.C., Hutchins L.J., Mazurkiewicz S.E., Needham A.M., Heal D.J. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, Sibutramine, in the rat. Br. J. Pharmacol. 121(8):1997;1613-1618.
16. Kiso T., Namikawa T., Tokunaga T., Sawada K., Kakita T., Shogaki T., Ohtsubo Y. Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1- propenyl]phenoxy]acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice. Biol. Pharm. Bull. 22(10):1999;1073-1078.
17. Klebig M.L., Wilkinson J.E., Geisler J.G., Woychik R.P. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4728-4732.
18. Klein S. The war against obesity: attacking a new front. Am. J. Clin. Nutr. 69(6):1999;1061-1063.
19. Kopelman P.J. Obesity as a medical problem. Nature. 404:2000;635-643.
20. Leibel R.L., Chung W.K., Chua S.C. The molecular genetics of rodent single gene obesities. J. Biol. Chem. 272:1997;31937-31940.
21. y) mutation. Proc. Natl. Acad. Sci. U. S. A. 91:1994;2562-2566.
22. Miller M.W., Duhl D.M.J., Vrieling H., Cordes S.P., Ollmann M.M., Winkes B.M., Barsh G.S. Cloning of mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev. 7:1993;454-467.
23. Ohki-Hamazaki H., Watase K., Yamamoto K., Ogura H., Yamano M., Yamada K., Maeno H., Imaki J., Kikuyama S., Wada E., Wada K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature. 390:1997;165-169.
24. Ohki-Hamazaki H., Sakai Y., Kamata K., Ogura H., Okuyama S., Watase K., Yamada K., Wada K. Functional properties of two bombesin-like peptide receptors revealed by the analysis of mice lacking neuromedin B receptor. J. Neurosci. 19(3):1999;948-954.
25. Phillips M.S., Liu Q., Hammond H.A., Dugan V., Hey P.J., Caskey C.J., Hess J.F. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 13:1996;18-19.
26. Robinson S.W., Dinulescu D.M., Cone R.D. Genetic models of obesity and energy balance in the mouse. Annu. Rev. Genet. 34:2000;687-745.
27. Routh V.H., Murakami D.M., Stern J.S., Fuller C.A., Horwitz B.A. Neuronal activity in hypothalamic nuclei of obese and lean Zucker rats. Int. J. Obes. 14(10):1990;879-891.
28. Savontaus E., Pesonen U., Rouru J., Huupponen R., Koulu M. Effects of ZD7114, a selective beta3-adrenoceptor agonist, on neuroendocrine mechanisms controlling energy balance. Eur. J. Pharmacol. 347(2-3):1998;265-274.
29. Shaw W.N. Long-term treatment of obese Zucker rats with LY25582 and other appetite suppressants. Pharmacol. Biochem. Behav. 46(3):1993;653-659.
30. Shimizu H., Uehara Y., Negishi M., Shimomura Y., Takahashi M., Fukatsu A., Takahashi S., Tanaka Y., Kashima K., Kobayashi I. Altered monoamine metabolism in the hypothalamus of the genetically obese yellow (Ay/a) mouse. Exp. Clin. Endocrinol. 99(1):1992;45-48.
31. Spindel E.R., Giladi E., Brehm P., Goodman R.H., Segerson T.P. Cloning and functional characterization of complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol. Endocrinol. 4:1990;1956-1963.
32. Stock M.J. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int. J. Obes. 21(Supplement 1):1997;S25-S29.
33. Wada E., Way J., Shapira H., Kusano K., Lebacq-Verheyden A.M., Coy D., Jensen R., Battey J.F. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor. Neuron. 6:1991;421-430.
34. Wada E., Watase K., Yamada K., Ogura H., Yamano M., Inomata Y., Eguchi J., Yamamoto K., Sunday M.E., Maeno H., Mikoshiba K., Ohki-Hamazaki H., Wada K. Generation and characterization of mice lacking gastrin-releasing peptide receptor. Biochem. Biophys. Res. Commun. 239(1):1997;28-33.
35. White D.W., Wang D.W., Chua S.C. Jr., Morgenstern J.P., Leibel R.L., Baumann H., Tartaglia L.A. Constitutive and impaired signaling of leptin receptors containing the Gln->Pro extracellular domain fatty mutation. Proc. Natl. Acad. Sci. 94:1997;10657-10662.
36. Wickelgren I. Obesity: how big a problem? Science. 280:1998;1364-1367.
37. Yamashita T., Murakami T., Iida M., Kuwajima M., Shima K. Leptin receptor of Zucker fatty rat performs reduced signal transduction. Diabetes. 46:1997;1077-1080.